Flawed research abstract leads to ivermectin falsehoods
Associated PressCLAIM: A recently published study shows that ivermectin is more effective than remdesivir in reducing mortality when treating COVID-19. Several Twitter accounts that have previously spread COVID-19 misinformation to their large followings shared a link to the abstract, titled: “Treatment with Ivermectin Is Associated with Decreased Mortality in COVID-19 Patients: Analysis of a National Federated Database.” But claims that suggest the abstract supports using ivermectin for COVID-19 patients fail to acknowledge several key issues. And so when you compare ivermectin versus remdesivir, de facto, what you’re doing, is you’re comparing somebody who is well enough to get treated outside the hospital versus somebody who’s sick enough to require treatment in the hospital.” Mark explained that the highest quality scientific evidence comes from prospective, blinded, randomized trials. He said that a retrospective, observational study with confounders such as this one, would yield “really low quality evidence.” He pointed out that most people sharing the abstract online likely weren’t aware of the difference. “It shows a reduction in mortality when one thing was given versus something else, and that can totally confuse people if you’re not well-versed in how we do studies and what makes a good study versus a less good study.” Ivermectin is not authorized or approved by FDA for use against COVID-19, and most health experts and agencies recommend against prescribing the anti-parasite drug for this purpose.